{"id":"177lu-pmsa-617","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Xerostomia (dry mouth)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Kidney toxicity"}]},"_chembl":{"chemblId":"CHEMBL3707297","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a theranostic radiopharmaceutical combining a PSMA-targeting ligand (617) with the beta-emitting isotope lutetium-177. It binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells and delivers localized radiation to kill tumor cells while minimizing exposure to healthy tissue. This approach enables both imaging and therapeutic delivery to PSMA-positive lesions.","oneSentence":"177Lu-PMSA-617 is a radioligand therapy that delivers lutetium-177 radiation directly to prostate cancer cells expressing PSMA, causing targeted cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:44.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"}]},"trialDetails":[{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pluvicto®"],"phase":"phase_3","status":"active","brandName":"177Lu-PMSA-617","genericName":"177Lu-PMSA-617","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-PMSA-617 is a treatment being studied for prostate cancer metastatic, specifically in patients with poor PSA response. It is a carbonic anhydrase IX binding agent, which is a type of BINDING AGENT according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}